These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 7669436

  • 1. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
    Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH.
    Bone; 1995 Jun; 16(6):603-10. PubMed ID: 7669436
    [Abstract] [Full Text] [Related]

  • 2. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM.
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [Abstract] [Full Text] [Related]

  • 3. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R.
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow.
    Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S, Takahashi HE.
    Bone; 1994 Jun; 15(6):717-23. PubMed ID: 7873302
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 9. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD.
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Advantages of concurrent use of anabolic and antiresorptive agents over single use of these agents in increasing trabecular bone volume, connectivity, and biomechanical competence of rat vertebrae.
    Kobayashi S, Shimizu T, Mehdi R, Nawata M, Kojima S, Tsutsumimoto T, Iorio R, Takaoka K.
    Bone; 1999 Dec; 25(6):703-12. PubMed ID: 10593416
    [Abstract] [Full Text] [Related]

  • 12. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
    Hodsman AB, Fraher LJ.
    Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
    [Abstract] [Full Text] [Related]

  • 13. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY.
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [Abstract] [Full Text] [Related]

  • 14. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).
    Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L.
    Bone; 1999 Sep; 25(3):301-9. PubMed ID: 10495134
    [Abstract] [Full Text] [Related]

  • 15. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL, Loft AG, Møller N, Weeke J, Eriksen EF, Mosekilde L, Charles P.
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [Abstract] [Full Text] [Related]

  • 16. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
    Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY.
    J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women.
    Tang Y, Xia H, Kang L, Sun Q, Su Z, Hao C, Xue Y.
    Med Sci Monit; 2019 Jan 08; 25():259-268. PubMed ID: 30620727
    [Abstract] [Full Text] [Related]

  • 20. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C, Rapado A, Díaz Diego EM, Díaz Martín MA, Aguirre C, López Gavilanes E, Díaz Curiel M.
    Calcif Tissue Int; 1996 Aug 08; 59(2):95-9. PubMed ID: 8687976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.